The group “Thrombotic thrombocytopenic purpura” (head: Paul Coppo) is involved in the identification of innovative approaches to tackle autoimmune disorders. The group uses thrombotic thrombocytopenic purpura (TTP) as a disease model to understand the immune response towards specific self-proteins. Through a translational approach, we investigate the reasons for the development of pathogenic antibodies directed against the VWF-cleaving protease ADAMTS13. Our aim is also to characterize B cell populations involved in their production, phenotypically and using gene expression profiling, to target more specifically immune cells in this disease. A strength of the group is its attachment to the French national reference center for rare diseases CNR-MAT, involved in the management of patients with TTP and other immune-hematological diseases of hemostasis, led by Prof. Paul Coppo.
